Optimizing Vaccine Allocation to Combat the COVID-19 Pandemic

The outbreak of COVID-19 has spurred extensive research worldwide to develop a vaccine. However, when a vaccine becomes available, limited production and distribution capabilities will likely lead to another challenge: who to prioritize for vaccination to mitigate the near-end impact of the pandemic? To tackle that question, this paper first expands a state-of-the-art epidemiological model, called DELPHI, to capture the effects of vaccinations and the variability in mortality rates across subpopulations. It then integrates this predictive model into a prescriptive model to optimize vaccine allocation, formulated as a bilinear, non-convex optimization model. To solve it, this paper proposes a coordinate descent algorithm that iterates between optimizing vaccine allocations and simulating the dynamics of the pandemic. We implement the model and algorithm using real-world data in the United States. All else equal, the optimized vaccine allocation prioritizes states with a large number of projected cases and subpopulations facing higher risks (e.g., older ones). Ultimately, the optimized vaccine allocation can reduce the death toll of the pandemic by an estimated 10-25%, or 10,000-20,000 deaths over a three-month period in the United States alone.

[1]  Ira M. Longini,et al.  Optimizing Vaccine Allocation at Different Points in Time during an Epidemic , 2010, PloS one.

[2]  Lynnette Brammer,et al.  Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[3]  Jian-ming Wang,et al.  Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China , 2020, Science China Life Sciences.

[4]  S. Plotkin,et al.  The complexity and cost of vaccine manufacturing – An overview , 2017, Vaccine.

[5]  Richard C. Larson,et al.  Multiregional Dynamic Vaccine Allocation During an Influenza Epidemic , 2013 .

[6]  Ralph L. Keeney,et al.  Repeated Commit-or-Defer Decisions with a Deadline: The Influenza Vaccine Composition , 2008, Oper. Res..

[7]  M. L. Li,et al.  Forecasting COVID-19 and Analyzing the Effect of Government Interventions , 2020, medRxiv.

[8]  Anne Kimball,et al.  Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility , 2020, The New England journal of medicine.

[9]  D. Bertsimas,et al.  From predictions to prescriptions: A data-driven response to COVID-19 , 2020, Health Care Management Science.

[10]  W. Cornwall Just 50% of Americans plan to get a COVID-19 vaccine. Here’s how to win over the rest , 2020 .

[11]  Erwan L'Her,et al.  Compassionate Use of Remdesivir for Patients with Severe Covid-19 , 2020, The New England journal of medicine.

[12]  N. Lurie,et al.  Developing Covid-19 Vaccines at Pandemic Speed. , 2020, The New England journal of medicine.

[13]  Xiaolong Qi,et al.  Real estimates of mortality following COVID-19 infection , 2020, The Lancet Infectious Diseases.

[14]  J. Medlock,et al.  Optimizing Influenza Vaccine Distribution , 2009, Science.

[15]  G. Chowell,et al.  Modeling Optimal Age-Specific Vaccination Strategies Against Pandemic Influenza , 2011, Bulletin of Mathematical Biology.

[16]  Stephen L. Jones,et al.  Racial and ethnic disparities in SARS-CoV-2 pandemic: analysis of a COVID-19 observational registry for a diverse US metropolitan population , 2020, BMJ Open.

[17]  Li Yan,et al.  Evaluation of the clinical characteristics of suspected or confirmed cases of COVID-19 during home care with isolation: A new retrospective analysis based on O2O , 2020, medRxiv.

[18]  Ezekiel J Emanuel,et al.  Who Should Get Influenza Vaccine When Not All Can? , 2006, Science.

[19]  M. Halloran,et al.  Finding optimal vaccination strategies for pandemic influenza using genetic algorithms. , 2005, Journal of theoretical biology.

[20]  Z. Memish,et al.  The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China , 2020, International Journal of Infectious Diseases.

[21]  Alan S. Perelson,et al.  Optimization of Influenza Vaccine Selection , 2005, Oper. Res..

[22]  Shibo Jiang,et al.  Current development of COVID-19 diagnostics, vaccines and therapeutics , 2020, Microbes and Infection.

[23]  Soo-Haeng Cho,et al.  The Optimal Composition of Influenza Vaccines Subject to Random Production Yields , 2010, Manuf. Serv. Oper. Manag..

[24]  David Simchi-Levi,et al.  A Game-Theoretic Model of International Influenza Vaccination Coordination , 2013, Manag. Sci..

[25]  Gerardo Chowell,et al.  Adaptive Vaccination Strategies to Mitigate Pandemic Influenza: Mexico as a Case Study , 2009, PloS one.

[26]  M. Lipsitch,et al.  Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period , 2020, Science.

[27]  A. Langworthy,et al.  An influenza simulation model for immunization studies. , 1976, American journal of epidemiology.

[28]  Rommert Dekker,et al.  Literature review: The vaccine supply chain , 2017, Eur. J. Oper. Res..

[29]  Jorge Nocedal,et al.  A trust region method based on interior point techniques for nonlinear programming , 2000, Math. Program..

[30]  M. Bajpai,et al.  Study of Non-Pharmacological Interventions on COVID-19 Spread , 2020, medRxiv.

[31]  Yonatan H. Grad,et al.  Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period , 2020, Science.

[32]  Nico Vandaele,et al.  A review of integrated supply chain network design models: Key issues for vaccine supply chains , 2016 .

[33]  Nathaniel Hupert,et al.  Clinical Characteristics of Covid-19 in New York City , 2020, The New England journal of medicine.

[34]  Sheldon Howard Jacobson,et al.  Pediatric vaccine procurement policy: The monopsonist's problem , 2011 .

[35]  Brian T. Denton,et al.  Optimal two-phase vaccine allocation to geographically different regions under uncertainty , 2014, Eur. J. Oper. Res..

[36]  Marc Lipsitch,et al.  Quantifying bias of COVID-19 prevalence and severity estimates in Wuhan, China that depend on reported cases in international travelers , 2020, medRxiv.

[37]  Jeffrey W. Herrmann,et al.  Montgomery County's Public Health Service Uses Operations Research to Plan Emergency Mass Dispensing and Vaccination Clinics , 2006, Interfaces.

[38]  Sheldon H Jacobson,et al.  Stockpile levels for pediatric vaccines: how much is enough? , 2006, Vaccine.

[39]  Rubén A. Proaño,et al.  An analysis of the pediatric vaccine supply shortage problem , 2006, Health care management science.

[40]  An Pan,et al.  Evolving Epidemiology and Impact of Non-pharmaceutical Interventions on the Outbreak of Coronavirus Disease 2019 in Wuhan, China , 2020, medRxiv.

[41]  Hannah R. Meredith,et al.  The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application , 2020, Annals of Internal Medicine.

[42]  Matt J. Keeling,et al.  Optimal but unequitable prophylactic distribution of vaccine , 2012, Epidemics.

[43]  Cecile Viboud,et al.  Vaccinating to Protect a Vulnerable Subpopulation , 2007, PLoS medicine.

[44]  Stephen L. Jones,et al.  Racial and ethnic disparities in SARS-CoV-2 pandemic: analysis of a COVID-19 observational registry for a diverse US metropolitan population , 2020, BMJ Open.

[45]  Jeffrey C. Lagarias,et al.  Convergence Properties of the Nelder-Mead Simplex Method in Low Dimensions , 1998, SIAM J. Optim..

[46]  E. Emanuel,et al.  An ethical framework for global vaccine allocation , 2020, Science.

[47]  Ozgur M. Araz,et al.  Geographic prioritization of distributing pandemic influenza vaccines , 2012, Health care management science.

[48]  Wenwu Sun,et al.  Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019 , 2020, medRxiv.

[49]  M. Koopmans,et al.  SARS-CoV-2 infection in 86 healthcare workers in two Dutch hospitals in March 2020 , 2020, medRxiv.

[50]  M. Halloran,et al.  Strategies for Pandemic and Seasonal Influenza Vaccination of Schoolchildren in the United States , 2009, American journal of epidemiology.

[51]  Matthew W. Tanner,et al.  Finding optimal vaccination strategies under parameter uncertainty using stochastic programming. , 2008, Mathematical biosciences.

[52]  Robert J. Cerfolio,et al.  Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City , 2020, medRxiv.

[53]  Peng Sun,et al.  Selfish Drug Allocation for Containing an International Influenza Pandemic at the Onset , 2009, Oper. Res..

[54]  M. Elizabeth Halloran,et al.  Optimal Vaccine Allocation for the Early Mitigation of Pandemic Influenza , 2013, PLoS Comput. Biol..

[55]  I. Longini,et al.  An optimization model for influenza A epidemics , 1978 .

[56]  C. Viboud,et al.  Adaptive vaccination strategies to mitigate pandemic influenza , 2009, PLoS currents.

[57]  Cecile Viboud,et al.  Impact of cross-protective vaccines on epidemiological and evolutionary dynamics of influenza , 2012, Proceedings of the National Academy of Sciences.

[58]  Barney S. Graham,et al.  Rapid COVID-19 vaccine development , 2020, Science.

[59]  Stefan Wager,et al.  Valuing Lead Time , 2013 .

[60]  G. Tiram,et al.  Immune-mediated approaches against COVID-19 , 2020, Nature Nanotechnology.

[61]  Judith R Kaufmann,et al.  Vaccine supply chains need to be better funded and strengthened, or lives will be at risk. , 2011, Health affairs.

[62]  Steven G. Krantz,et al.  Level of underreporting including underdiagnosis before the first peak of COVID-19 in various countries: Preliminary retrospective results based on wavelets and deterministic modeling , 2020, Infection Control & Hospital Epidemiology.

[63]  R. Watson,et al.  On an epidemic in a stratified population , 1972, Journal of Applied Probability.

[64]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[65]  David Simchi-Levi,et al.  Supply Chain Coordination and Influenza Vaccination , 2008, Oper. Res..

[66]  David M. Wirth,et al.  COVID-19 vaccine development and a potential nanomaterial path forward , 2020, Nature Nanotechnology.

[67]  Tapas K. Das,et al.  A predictive decision-aid methodology for dynamic mitigation of influenza pandemics , 2011, OR Spectr..

[68]  Nan Yang,et al.  Competition Under Generalized Attraction Models: Applications to Quality Competition Under Yield Uncertainty , 2009, Manag. Sci..

[69]  Sarang Deo,et al.  Consumption Externality and Yield Uncertainty in the Influenza Vaccine Supply Chain: Interventions in Demand and Supply Sides , 2012, Manag. Sci..